Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer.

被引：0
|
作者：
Osterlind, K
Sánchez, JM
Zatloukal, P
Hamm, J
Belani, CP
Kim, E
Felip, E
Johri, A
Berton, M
Sklenar, I
机构：
[1] Herlev Univ Hosp, DK-2730 Herlev, Denmark
[2] Hosp Germans Trias & Pujol, Barcelona, Spain
[3] Univ Hosp Na Bulovce, Prague, Czech Republic
[4] Norton Healthcare Hosp Inc, Louisville, KY USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Vall Hebron Univ Hosp, Barcelona, Spain
[8] Novartis Pharmaceut Corp, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：647S / 647S
页数：1
相关论文
共 50 条
  • [1] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer
    Sanchez, J. M.
    Osterlind, K.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Sklenar, I.
    John, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 327
  • [2] Phase I/II trial of patupilone once every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Osterlind, K
    Sánchez, J
    Zatloukai, P
    Hamm, J
    Belani, C
    Kim, E
    Felip, E
    Sklenar, I
    Berton, M
    Johri, A
    LUNG CANCER, 2005, 49 : S261 - S261
  • [3] A phase I/II dose-escalation trial of patupilone (EPO906) administered every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Oesterlind, Kell
    Sanchez, Jose
    Zatloukal, Petr
    Perry, Michael
    Hamm, John
    Belani, Chandra
    Kim, Edward
    Vansteenkiste, Johan
    Felip, Enriqueta
    Berton, Myriam
    ANNALS OF ONCOLOGY, 2004, 15 : 167 - 167
  • [4] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [5] A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC).
    Oesterlind, K
    Sanchez, JM
    Zatloukal, P
    Perry, MC
    Hamm, JT
    Belani, CP
    Kim, ES
    Vansteenkiste, JF
    Felip, E
    Berton, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 678S - 678S
  • [6] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer
    Smit, W. M.
    Sufliarsky, J.
    Spanik, S.
    Wagnerova, M.
    Kaye, S.
    Oza, A. M.
    Gore, M.
    Williams, K. J.
    Johri, A.
    Huinink, W. W. ten Bokkel
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 262
  • [7] Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial
    Koukourakis, MI
    Kourousis, C
    Kamilaki, M
    Koukouraki, S
    Giatromanolaki, A
    Kakolyris, S
    Kotsakis, A
    Androulakis, N
    Bahlitzanakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) : 838 - 844
  • [8] Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC):: A phase I/II trial.
    Sanchez, J. M.
    Mellemgaard, A.
    Perry, M.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 390S - 390S
  • [9] Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer
    Shepherd, FA
    Latreille, J
    Paul, K
    Eisenhauer, E
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 84 - 90
  • [10] A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    Andersen, Jon L.
    Holm, Bente
    Rasmussen, Trine S.
    Mellemgaard, Anders
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1201 - S1202
12345